Hongjie Li, Dechun Feng, Yan Cai, Yudong Liu, Mingjiang Xu, Xiaogang Xiang, Zhou Zhou, Qiang Xia, Mariana J. Kaplan, Xiaoni Kong, Bin Gao – 10 April 2018 – Lipocalin‐2 (LCN2), also known as neutrophil gelatinase‐associated lipocalin (NGAL), a key antibacterial protein, is highly elevated in patients with end‐stage liver disease that is often associated with bacterial infection. LCN2 is expressed at high levels in both hepatocytes and neutrophils; however, how hepatocyte‐derived and neutrophil‐derived LCN2 cooperate to combat bacterial infection remains unclear.

Catherine E. Kling, James D. Perkins, Jorge D. Reyes, Martin I. Montenovo – 10 April 2018 – In this era of organ scarcity, living donor liver transplantation (LDLT) is an alternative to using deceased donors, and in Western countries, it is more often used for recipients with low Model for End‐Stage Liver Disease (MELD) scores. We sought to compare the patient survival and graft survival between recipients of liver transplantation from living donors and donation after circulatory death (DCD) donors in patients with low MELD scores.

Pilar Leal‐Leyte, Greg J. McKenna, Richard M. Ruiz, Tiffany L. Anthony, Giovanna Saracino, Giuliano Testa, Goran B. Klintmalm, Peter T. W. Kim – 10 April 2018 – Bile duct size discrepancy in liver transplantation may increase the risk of biliary complications (BCs). The aim of this study was to evaluate the safety and outcomes of the eversion bile duct anastomosis technique in deceased donor liver transplantation (DDLT) with duct‐to‐duct anastomosis.

Hyun Goo Woo, Yoon Jun Kim – 10 April 2018

Dominique Wendum, Richard Layese, Nathalie Ganne‐Carrié, Valérie Bourcier, Fatiha Merabtene, Carole Cagnot, Emmanuel Sauce, Nathalie Barget, Pierre Bedossa, Benoit Terris, Janick Selves, Paulette Bioulac‐Sage, Nathalie Sturm, Christophe Sattonnet, Pierre Nahon, Françoise Roudot‐Thoraval, Marianne Ziol, for the ANRS CO12 CirVir Group – 10 April 2018 – Progenitor‐derived regeneration gives rise to the aberrant expression of biliary markers such as cytokeratin 7 (K7) and epithelial cell adhesion molecule (EpCAM) in hepatocytes.

Feifei Zhang, Zhimin Hu, Gaopeng Li, Shaofeng Huo, Fengguang Ma, Aoyuan Cui, Yaqian Xue, Yamei Han, Qi Gong, Jing Gao, Hua Bian, Zhuoxian Meng, Haifu Wu, Gang Long, Yi Tan, Yan Zhang, Xu Lin, Xin Gao, Aimin Xu, Yu Li – 10 April 2018 – Insulin is critical for the regulation of de novo fatty acid synthesis, which converts glucose to lipid in the liver. However, how insulin signals are transduced into the cell and then regulate lipogenesis remains to be fully understood.

Jordan M Cloyd, Timothy M Pawlik – 7 April 2018

Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang – 7 April 2018 – Hepatocellular carcinoma (HCC) imposes a heavy disease burden on China due to its high morbidity and mortality. China accounts for about 50% of the total new cases and deaths worldwide. Most cases are related to hepatitis B virus (HBV) infection and are associated with cirrhosis at diagnosis. Antiviral treatment with nucleos(t)ide analogues (NAs) after resection in HBV‐related HCC can reduce recurrence and improve survival. Such treatment is in fact recommended by Chinese guidelines.

Edward Yang, Lan Peng, William M. Lee – 6 April 2018

Dirk J. van der Windt, Vikas Sud, Hongji Zhang, Patrick R. Varley, Julie Goswami, Hamza O. Yazdani, Samer Tohme, Patricia Loughran, Robert M. O'Doherty, Marta I. Minervini, Hai Huang, Richard L. Simmons, Allan Tsung – 6 April 2018 – Nonalcoholic steatohepatitis (NASH) is a progressive, inflammatory form of fatty liver disease. It is the most rapidly rising risk factor for the development of hepatocellular carcinoma (HCC), which can arise in NASH with or without cirrhosis. The inflammatory signals promoting the progression of NASH to HCC remain largely unknown.